Loading...
Docoh

Odonate Therapeutics (ODTC)

Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Odonate’s initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Odonate’s goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.

Company profile

ODTC stock data

Calendar

10 Nov 21
25 Jun 22
31 Dec 22
Quarter (USD) Sep 21 Jun 21 Mar 21 Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 95.74M 95.74M 95.74M 95.74M 95.74M 95.74M
Cash burn (monthly) 5.03M 7.77M 4.67M 8.53M 5.03M 7.88M
Cash used (since last report) 44.58M 68.82M 41.39M 75.53M 44.58M 69.78M
Cash remaining 51.16M 26.92M 54.35M 20.21M 51.16M 25.96M
Runway (months of cash) 10.2 3.5 11.6 2.4 10.2 3.3

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
10 Dec 21 EcoR1 Capital Common Stock Sell Dispose S Yes No 1.5549 545,000 847.42K 0
10 Dec 21 EcoR1 Capital Common Stock Sell Dispose S Yes No 1.66 5,000,000 8.3M 545,000
9 Dec 21 EcoR1 Capital Common Stock Sell Dispose S Yes No 1.819 156,669 284.98K 5,545,000
1 Dec 21 EcoR1 Capital Common Stock Sell Dispose S Yes No 1.66 185,941 308.66K 5,701,669
1 Dec 21 EcoR1 Capital Common Stock Buy Acquire P Yes No 1.66 185,941 308.66K 5,701,669
24 Nov 21 Boxer Capital Common Stock Sell Dispose S No No 1.5684 200,000 313.68K 4,207,086
22 Nov 21 Boxer Capital Common Stock Sell Dispose S No No 1.5483 200,000 309.66K 4,407,086
19 Nov 21 Tang Kevin C Common Stock Sell Dispose S Yes No 1.9161 365,289 699.93K 12,767,435
19 Nov 21 Boxer Capital Common Stock Sell Dispose S No No 1.8419 150,000 276.29K 4,607,086
18 Nov 21 Tang Kevin C Common Stock Sell Dispose S Yes No 1.8925 381,842 722.64K 13,132,724
96.6% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 51 59 -13.6%
Opened positions 10 6 +66.7%
Closed positions 18 16 +12.5%
Increased positions 19 12 +58.3%
Reduced positions 13 27 -51.9%
13F shares Current Prev Q Change
Total value 64.25M 348.35M -81.6%
Total shares 37.2M 48.66M -23.6%
Total puts 22.4K 35.5K -36.9%
Total calls 600 25.4K -97.6%
Total put/call ratio 37.3 1.4 +2571.2%
Largest owners Shares Value Change
Tang Capital Partners 12.96M $30.19M -19.2%
Tang Capital Management 12.77M $17.24M -17.7%
Boxer Capital 4.21M $5.68M -25.0%
Ikarian Capital 1.34M $1.81M -27.2%
Vanguard 964.82K $1.3M +0.3%
Samsara BioCapital 700.42K $946K 0.0%
Acadian Asset Management 416.74K $561K +14.0%
BLK Blackrock 400.91K $541K -45.2%
D. E. Shaw & Co. 374.2K $505K +60.4%
Geode Capital Management 352.81K $476K +1.3%
Largest transactions Shares Bought/sold Change
EcoR1 Capital 0 -3.73M EXIT
Tang Capital Partners 12.96M -3.07M -19.2%
Tang Capital Management 12.77M -2.75M -17.7%
Boxer Capital 4.21M -1.4M -25.0%
Ikarian Capital 1.34M -500K -27.2%
MS Morgan Stanley 18.02K -387.88K -95.6%
Assenagon Asset Management 0 -346.3K EXIT
BLK Blackrock 400.91K -330.58K -45.2%
Prosight Management 298.9K +298.9K NEW
MYDA Advisors 350.07K +260.09K +289.1%

Financial report summary

?
Competition
Athenex
Management Discussion
  • All of our research and development expense incurred through March 22, 2021 had been incurred in connection with the development of tesetaxel and since then includes the wind-down of tesetaxel-related operations. Research and development expense includes non-personnel-related and personnel-related expense. Non-personnel-related expense primarily consists of expense incurred prior to the discontinuation of development of tesetaxel and includes expense related to: (i) clinical study site payments; (ii) manufacturing development, including manufacturing registration and validation batches of tesetaxel; (iii) acquiring clinical study materials and the clinical study supply chain; (iv) clinical and quality systems; and (v) pharmacokinetic studies. Personnel-related expense includes expense related to salaries, bonuses and benefits, restructuring expense and equity-based compensation for personnel engaged in research and development functions. We expect our research and development expense to be de minimis in the near term due to the discontinuation of development of tesetaxel and wind-down of tesetaxel-related operations.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: admission, burdensome, constitute, de, documentation, earlier, inclusive, joint, principle, protracted, reached, reimbursement, Settlement, stay, stockholder
Removed: allegedly, attorney, award, range, stage, sustained, unable